{"entity":{"id":"nct05615623","kind":"trial","name":"Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG","aka":[],"tldr":"A phase 1/2 trial of Doxorubicin in brain and spinal cord tumours, run by InSightec, active and no longer recruiting.","summary":"Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG is a phase 1/2 interventional study registered as NCT05615623 by InSightec, with 10 participants enrolled, started 2023-01-04 and due to reach its primary completion in 2026-06. Interventions recorded: Exablate and Doxorubicin.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05615623","url":"https://clinicaltrials.gov/study/NCT05615623"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["brain-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":["doxorubicin"],"companies":["insightec"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05615623","phase":"1/2","setting":"A Safety and Feasibility Study to Evaluate Blood Brain Barrier Disruption Using Exablate MR Guided Focused Ultrasound in Combination With Doxorubicin in Treating Pediatric Patients With Diffuse Intrinsic Pontine Gliomas (DIPG)","sponsor":"InSightec","enrolled":10,"outcomes":[]},"route":"/trials/nct05615623/","neighbours":{"cancer":[{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/"}],"drug":[{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"}],"company":[{"id":"insightec","kind":"company","name":"Insightec","route":"/companies/insightec/"}]}}